Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2019

View Archived Issues

AQAMAN: Heroic inhibitor restrains polyQ aggregation

Gilead presents first data for anti-HIV antibody GS-9722

Beijing Xuanyi Pharmasciences patents CDK4 and CDK6 inhibitors

Istituto Europeo di Oncologia discloses new KDM1A inhibitors

STING innate immune protein induces autophagy

Innate immune signaling complexes are multifunctional, programmable

Agios Pharmaceuticals synthesizes PKM activators

PROLONG study of Makena does not meet coprimary endpoints

GlaxoSmithKline identifies new compounds for tuberculosis

Saint Louis University discloses ESRRG inverse agonists

Interim phase I data reported for GS-6207

GlaxoSmithKline's GSK-2838232 shows activity in phase IIa study in patients with HIV

Discovery of new TRPV4 agonist as regulators of chondrogenic differentiation

Saniona initiates phase IIa study of Tesomet for hypothalamic obesity

FDA grants accelerated approval to Tecentriq plus chemotherapy in PD-L1-positive metastatic TNBC

Pharmacokinetic data on VRC-01 LS in HIV-exposed newborns reported

Topline results from first-in-human study of TLC-590 for postsurgical pain

Dicerna enrolling in phase II study of DCR-PHXC for primary hyperoxaluria

MGB Biopharma studies MGB-BP-3 for C. difficile-associated diarrhea in new phase IIa trial

UCL initiates phase I/II study of MSCTRAIL in metastatic NSCLC

ProQR initiates first-in-human study of QR-421a for Usher's syndrome type 2

FDA clears Rubius' IND application for phase Ib trial of RTX-134 for PKU

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.